Literature DB >> 19616703

Phase 0 trials: a platform for drug development?

.   

Abstract

Mesh:

Substances:

Year:  2009        PMID: 19616703     DOI: 10.1016/S0140-6736(09)61309-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee.

Authors:  S Percy Ivy; Lillian L Siu; Elizabeth Garrett-Mayer; Larry Rubinstein
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

2.  The statistics of phase 0 trials.

Authors:  Larry V Rubinstein; Seth M Steinberg; Shivaani Kummar; Robert Kinders; Ralph E Parchment; Anthony J Murgo; Joseph E Tomaszewski; James H Doroshow
Journal:  Stat Med       Date:  2010-05-10       Impact factor: 2.373

3.  Clinical Evaluation of a Defined Zeolite-Clinoptilolite Supplementation Effect on the Selected Blood Parameters of Patients.

Authors:  Sandra Kraljević Pavelić; Lara Saftić Martinović; Jasmina Simović Medica; Marta Žuvić; Željko Perdija; Dalibor Krpan; Sandra Eisenwagen; Tatjana Orct; Krešimir Pavelić
Journal:  Front Med (Lausanne)       Date:  2022-05-27

4.  A proof of concept 'phase zero' study of neurodevelopment using brain organoid models with Vis/near-infrared spectroscopy and electrophysiology.

Authors:  Anirban Dutta; Sneha Sudhakar Karanth; Mahasweta Bhattacharya; Michal Liput; Justyna Augustyniak; Mancheung Cheung; Ewa K Stachowiak; Michal K Stachowiak
Journal:  Sci Rep       Date:  2020-12-02       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.